Bella (Guangzhou) Intelligent Information Technology Co., Ltd. – Trademark Portfolio
Entity Type: 99
Bella (Guangzhou) Intelligent Information Technology Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include BELOVEDONE. The owner is based in Dist, Guangzhou,.
3F, No. 137 (Factory A1), Pacific
Industrial Zone, Xintang Town, Zengcheng
Dist, Guangzhou, 511340 , CN
Showing of trademarks Trademarks
Trademark Classifications
Bella (Guangzhou) Intelligent Information Technology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Frequently Asked Questions
How many trademarks does Bella (Guangzhou) Intelligent Information Technology Co., Ltd. have?
Bella (Guangzhou) Intelligent Information Technology Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does Bella (Guangzhou) Intelligent Information Technology Co., Ltd. file in?
Bella (Guangzhou) Intelligent Information Technology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 10 (Medical Apparatus). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Bella (Guangzhou) Intelligent Information Technology Co., Ltd.'s most well-known trademarks?
Bella (Guangzhou) Intelligent Information Technology Co., Ltd.'s registered trademark portfolio includes well-known marks such as BELOVEDONE. These are among 1 currently registered trademark in the portfolio.
What is Bella (Guangzhou) Intelligent Information Technology Co., Ltd.'s trademark registration success rate?
Bella (Guangzhou) Intelligent Information Technology Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.